Lineage Cell Therapeutics (LCTX) Operating Margin Growth (1y) (2011 - 2026)

Lineage Cell Therapeutics (LCTX) Operating Margin Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1,552.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1,536.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -170.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1,049.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Lineage Cell Therapeutics 267.08 Mn 203.18 Mn 1.73 Mn -708.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -708.00
Dec 31, 2025 7,908.00
Sep 30, 2025 -124.00
Jun 30, 2025 -29,868.00
Mar 31, 2025 2,820.00
Dec 31, 2024 12,652.00
Sep 30, 2024 43,651.00
Jun 30, 2024 -26,091.00
Mar 31, 2024 -18,291.00
Dec 31, 2023 4,199.00
Sep 30, 2023 -36,297.00
Jun 30, 2023 -6,279.00
Mar 31, 2023 -15,624.00
Dec 31, 2022 -29,021.00
Sep 30, 2022 12,630.00
Jun 30, 2022 128,982.00
Mar 31, 2022 168,094.00
Dec 31, 2021 160,043.00
Sep 30, 2021 87,630.00
Jun 30, 2021 27,574.00